Evidence map›Paper›PMID 34161353›Full record

ArticlePloS one2021

Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects.

Helena Escuin-Ordinas, Yining Liu, Lu Sun, Willy Hugo, Robert Dimatteo, Rong Rong Huang, Paige Krystofinski, Ariel Azhdam, Jordan Lee, Begoña Comin-Anduix and 5 more

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07463365 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase 1, Open-Label Clinical Trial to Assess the Safety, Tolerability, and Preliminary Efficacy Study of Topically Administered LUT017 Gel for Cutaneous Wound Healing

TypeinterventionalSponsorAntoni RibasRan2026 to 2027Enrolled18ConditionsVenous Leg Ulcer, Chronic Non-Healing Cutaneous Wounds, VLUArmsLUT017 gel
NCT07463378 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Phase 1, Open-Label Clinical Trial to Assess the Safety, Tolerability, and Preliminary Efficacy Study of a Single Dose of Topically Administered LUT017 Gel for Cutaneous Wound Healing in Volunteers With Healthy Skin

TypeinterventionalSponsorAntoni RibasRan2026 to 2027Enrolled9ConditionsWound Healing, Acute Skin WoundsArmsLUT017,Topical BRAF inhibitor
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  8. Gels (Basel, Switzerland) · 2024
    Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Helena Escuin-OrdinasDivision of Hematology/Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, United States of America.ORCID 0000-0003-0530-5906
Yining LiuDepartment of Chemical and Biomolecular Engineering, UCLA, Los Angeles, California, United States of America.
Lu SunDivision of Dermatology, Department of Medicine, UCLA, Los Angeles, California, United States of America.
Willy HugoDivision of Dermatology, Department of Medicine, UCLA, Los Angeles, California, United States of America.
Robert DimatteoDepartment of Chemical and Biomolecular Engineering, UCLA, Los Angeles, California, United States of America.
Rong Rong HuangDepartment of Pathology and Laboratory Medicine, UCLA, Los Angeles, California, United States of America.
Paige KrystofinskiDivision of Hematology/Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, United States of America.
Ariel AzhdamDivision of Hematology/Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, United States of America.
Jordan LeeDepartment of Dermatology, VA Greater Los Angeles Healthcare System-West Los Angeles, Los Angeles, California, United States of America.
Begoña Comin-AnduixDivision of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, California, United States of America.
Alistair J CochranDepartment of Pathology and Laboratory Medicine, UCLA, Los Angeles, California, United States of America.
Roger S LoDivision of Dermatology, Department of Medicine, UCLA, Los Angeles, California, United States of America.
Tatiana SeguraDepartment of Chemical and Biomolecular Engineering, UCLA, Los Angeles, California, United States of America.
Philip O ScumpiaDivision of Dermatology, Department of Medicine, UCLA, Los Angeles, California, United States of America.
Antoni RibasDivision of Hematology/Oncology, Department of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, United States of America.
University of California, Los Angeles · USVA Greater Los Angeles Healthcare System · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Project 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMASP01CA168585 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RIBAS, ANTONI · 2013 to 2017
$8.4M
NCI NIH HHS P01 CA168585NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R35 CA197633
6 · The paper itself

Abstract

Wound healing is a multi-step process to rapidly restore the barrier function. This process is often impaired in diabetic patients resulting in chronic wounds and amputation. We previously found that paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway via topical administration of the BRAF inhibitor vemurafenib accelerates wound healing by activating keratinocyte proliferation and reepithelialization pathways in healthy mice. Herein, we investigated whether this wound healing acceleration also occurs in impaired diabetic wounds and found that topical vemurafenib not only improves wound healing in a murine diabetic wound model but unexpectedly promotes hair follicle regeneration. Hair follicles expressing Sox-9 and K15 surrounded by CD34+ stroma were found in wounds of diabetic and non-diabetic mice, and their formation can be prevented by blocking downstream MEK signaling. Thus, topically applied BRAF inhibitors may accelerate wound healing, and promote the restoration of improved skin architecture in both normal and impaired wounds.

Indexed as

Administration, TopicalAnimalsbeta CateninDiabetes Mellitus, ExperimentalFemaleHair FollicleMiceMice, Inbred BALB CMice, ObeseProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRegenerationSkinVemurafenibWnt Signaling PathwayWound Healingbeta CateninProtein Kinase InhibitorsProto-Oncogene Proteins B-rafVemurafenib

Identifiers

PMID34161353
PMCPMC8221471
OpenAlexW3177411132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.